Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01105065 |
Recruitment Status :
Completed
First Posted : April 16, 2010
Results First Posted : October 27, 2016
Last Update Posted : April 4, 2017
|
Sponsor:
Massachusetts Eye and Ear Infirmary
Information provided by (Responsible Party):
Louis Pasquale, MD, Massachusetts Eye and Ear Infirmary
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Glaucoma |
Intervention |
Drug: brimonidine 0.15% |
Enrollment | 46 |
Participant Flow
Recruitment Details | |
Pre-assignment Details | 46 participants enrolled but only 23 had retinal vascular dysregulation. |
Arm/Group Title | Patients With RVD |
---|---|
![]() |
Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks. Alphagan (brimonidine) 0.15%: One drop in each eye three times a day for 8 weeks. |
Period Title: Overall Study | |
Started | 23 |
Completed | 17 |
Not Completed | 6 |
Reason Not Completed | |
Adverse Event | 5 |
Technical Problems | 1 |
Baseline Characteristics
Arm/Group Title | Patients With RVD | |
---|---|---|
![]() |
Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks. Alphagan (brimonidine) 0.15%: One drop in each eye three times a day for 8 weeks. |
|
Overall Number of Baseline Participants | 23 | |
![]() |
[Not Specified]
|
|
Age, Continuous
[1] Mean (Standard Deviation) Unit of measure: Years |
||
Number Analyzed | 23 participants | |
57.1 (10.8) | ||
[1]
Measure Description: age range: 35 years to 80 years
|
||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 23 participants | |
Female |
12 52.2%
|
|
Male |
11 47.8%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||
United States | Number Analyzed | 23 participants |
23 |
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Louis R. Pasquale, MD |
Organization: | Massachusetts Eye and Ear Infirmary |
Phone: | 617-573-4270 |
EMail: | Louis_Pasquale@meei.harvard.edu |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Louis Pasquale, MD, Massachusetts Eye and Ear Infirmary |
ClinicalTrials.gov Identifier: | NCT01105065 |
Other Study ID Numbers: |
10-03-019 (75643) |
First Submitted: | April 14, 2010 |
First Posted: | April 16, 2010 |
Results First Submitted: | December 7, 2014 |
Results First Posted: | October 27, 2016 |
Last Update Posted: | April 4, 2017 |